Aquipta

RSS

atogepant

Authorised
This medicine is authorised for use in the European Union.

Overview

Aquipta is a medicine used to prevent migraines in adults who have migraines at least 4 days a month.

Aquipta contains the active substance atogepant.

This EPAR was last updated on 25/08/2023

Authorisation details

Product details
Name
Aquipta
Agency product number
EMEA/H/C/005871
Active substance
atogepant
International non-proprietary name (INN) or common name
atogepant
Therapeutic area (MeSH)
Migraine Disorders
Anatomical therapeutic chemical (ATC) code
N02CD07
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
AbbVie Deutschland GmbH & Co. KG
Date of issue of marketing authorisation valid throughout the European Union
11/08/2023
Contact address

Knollstrasse
67061 Ludwigshafen
GERMANY

Product information

Aquipta - EMEA/H/C/005871 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Therapeutic indication

Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month

Assessment history

How useful was this page?

Add your rating
Average
1 rating